Posts

iPS-Derived Dopaminergic Cells Trial for Parkinson’s

In a groundbreaking advancement for Parkinson’s disease therapy, researchers hav...

EU Invests €8 Million to Propel Solar Fuel Innovations ...

The European Union is making notable advancements in renewable energy technologi...

Antiferromagnetic Quantum Anomalous Hall Transformations

In the rapidly evolving field of topological materials, the discovery and explor...

Targeted Sequencing Reveals Asian Lung Cancer Variants

In recent years, the landscape of cancer diagnostics has been revolutionized by ...

BAY-876 Blocks GLUT1, Triggers Cancer Cell Death

In a groundbreaking new study published in BMC Cancer, researchers have unveiled...

Uncovering Hidden Causes: Nontraditional Risk Factors I...

In a groundbreaking new study published in the prestigious journal Stroke, resea...

Machine Learning Unveils Bladder Cancer Stemness

In a groundbreaking advancement in bladder cancer research, scientists have unve...

CRS Score Predicts Outcomes in CRLM Patients

A groundbreaking study recently published in BMC Cancer has unveiled a robust pr...

Vanda Challenges FDA Over Limits on Off-Label Drug Comm...

Vanda Pharmaceuticals is pushing back against the U.S. Food and Drug Administrat...

Pfizer Decides Against Pursuing Lead Obesity Asset Amid...

Pfizer said that it had discovered a possible instance of medication-induced liv...

BMS’ Camzyos flops in Phase III non-obstructive hypertr...

BMS could soon face competition in the HCM space as Cytokinetics awaits a market...

Do in vivo CAR-T cell therapies have the potential to o...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the ...

ESCMID Global 2025: Climate-informed infectious disease...

At the ESCMID Global conference in Austria, the development of climate-informed ...

Coherus divests Udenyca franchise to Intas for up to $5...

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) f...

Ironwood’s shares sink as FDA demands new trial for lea...

The FDA will require an additional Phase III trial for apraglutide, the company'...